Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia

作者：Fozza Claudio^*; Corda Giovanna; Barraqueddu Francesca; Virdis Patrizia; Contini Salvatore; Galleu Antonio; Isoni Antonella; Dore Fausto; Angelucci Emanuele; Longinotti Maurizio

来源：Leukemia Research, 2015, 39(9): 957-963.

DOI：10.1016/j.leukres.2015.06.007

• Myelodysplastic syndromes
• Acute myeloid leukemia with multilineage dysplasia
• Azacitidine
• T-cell receptor (TCR) repertoire
• Flow cytometry
• Spectratyping

Patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with multilineage dysplasia show several immunological abnormalities. In this clinical setting, by combining flow cytometry and CDR3 spectratyping we monitored the kinetic of the T-cell repertoire during Azacitidine treatment, in order to explore its potential ability to reverse the immune derangement typical of these disorders. We firstly demonstrated by flow cytometry an increase in both CD4+ and CD8+ T-cell frequencies after starting treatment. Moreover, when monitored by spectratyping our patients showed significant changes in their T-cell receptor (TCR) CDR3 profiles, which were much more evident in helper T-cells. In fact, the frequency of BV (beta variable) subfamilies showing a skewed CDR3 profile significantly decreased from baseline to the following evaluations in CD4+ T-cells (81% vs. 70%). This pattern was even more pronounced in patients responding to Azacitidine (90% vs. 61%). Our data show that the overall derangement of the Tcell repertoire detectable in patients with MDS and AML with multilineage dysplasia gradually improves during Azacitidine treatment. These findings therefore suggest that Azacitidine could be potentially able, not only to restore the hematopoietic function, but also to reverse the immune derangement typical of these hematologic disorders.

• 出版日期2015-9